Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia

Cancer Control

Volumn 19, Issue 1, 2012, Pages 54-67

  Carballido, Estrella ^a   Veliz, Marays ^a   Komrokji, Rami ^a   Pinilla Ibarz, Javier ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUDARABINE; IMATINIB; IMMUNOGLOBULIN; LENALIDOMIDE; OFATUMUMAB; PEPTIDE VACCINE; POMALIDOMIDE; RITUXIMAB; THALIDOMIDE; TUMOR CELL VACCINE;

ACTIVE IMMUNIZATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CANDIDEMIA; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEBRILE NEUTROPENIA; GENE THERAPY; HUMAN; IMMUNOGENICITY; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; SKIN NODULE; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA;

EID: 83255170962     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900106     Document Type: Article

References (113)

1. Eriksson T, Björkman S, Roth B, et al. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000;52(7):807-817.
2. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90(5):955-961.
3. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-1499.
4. Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood. 1990;76(2):393-400.
5. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002;100(4):1215-1219.
6. Ribatti D, Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia. 2005;19:1525-1531.
7. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699-703.
8. Pawelec G, Schaudt K, Rehbein A, et al. Differential secretion of tumor necrosis factor-alpha and granulocyte/macrophage colony-stimulating factors but not interferon-gamma from CD4+ compared to CD8+ human T cell clones. Eur J Immunol. 1989;19(1):197-200.
9. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675-1680.
10. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
11. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9(11):1625-1630.
12. Muller GW, Corral LG, Shire MG, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem. 1996;39(17):3238-4320.
13. Aue G, Soto S, Valdez J, et al. Phase II trial of pulse dosed lenalidomide in previously treated chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 2010;116:1383.
14. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291-5297.
15. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-386.
16. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
17. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103(5):1787-1790.
18. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033-1045.
19. Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005;19(10):1788-1793.
20. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128(2):192-203.
21. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69(1-2):56-63.
22. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26(15):2519-2525.
23. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943-2950.
24. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006;7(6):480-488.
25. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67(2):746-755.
26. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide downregulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008;112(13):5180-5189.
27. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010;115(13):2619-2629.
28. Stebbing J, Benson C, Eisen T, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer. 2001;85(7):953-958.
29. Aragon-Ching JB, Dahut WL. The role of angiogenesis inhibitors in prostate cancer. Cancer J. 2008;14(1):20-25.
30. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration- resistant prostate cancer. J Clin Oncol. 2010;28(12):2070-2076.
31. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13): 3489-3498.
32. Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(9):1175-1181.
33. Maddocks K, Lapalombella R, Blum KA, et al. Preliminary results of a phase I study of lenalidomide in relapsed chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 2009;114 3446.
34. Wendtner CM, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Nov 15. Epub ahead of print.
35. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalid omide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34):5343-5349.
36. Ferrajoli A, Badoux XC, O'Brien S, et al. The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts). 2010;116:1395.
37. Veliz M, Santana R, Lancet JE, et al. Phase II study of lenalidomide in combination with rituximab for patients with CD5+/CD20+ hematologic malignancies who relapse or progress after rituximab. Interim analysis. Blood (ASH Annual Meeting Abstracts). 2009;114:2376.
38. Badoux X, O'Brien S, Wierda WG, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a phase II trial. Blood (ASH Annual Meeting Abstracts). 2010;116:2464.
39. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010;51(1):85-88.
40. Chanan-Khan AA, Ersing N, Krammer D, et al. Pro-Apoptotic effect of lenalidomide (L) in patients with chronic lymphocytic leukemia (CLL) is possibly mediated through interruption of the phosphatidylinositol pathway. Blood (ASH Annual Meeting Abstracts). 2006;108:2102.
41. Badoux X, Reuben J, Lee B, et al. Lenalidomide therapy is associated with normalization of lymphocyte populations and increase in immunoglobulin levels in elderly patients with chronic lymphocytic leukemia. Haematologica. 2009;94(suppl 3):S94. Abstract 10.31.
42. Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010;24(11):1972-1975.
43. Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med. 1999;77(2):282-293.
44. Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood. 1997;89(6):2015-2023.
45. Johnston JB, Daeninck P, Verburg L, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 1997;26(5-6):435-449.
46. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B cell chronic lymphocytic leukemia. Cancer Res. 1999;59(1):24-27.
47. Harris NL. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue and monocytoid B-cell lymphoma. Related entities that are distinct from other low-grade B-cell lymphomas. Arch Pathol Lab Med. 1993;117(8):771-775.
48. Ribera JM, Vinolas N, Urbano-Ispizua A, et al. "Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. Blood Cells. 1987;12(2):471-483.
49. Ziegler-Heitbrock HW, Schlag R, Flieger D, et al. Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood. 1989;73(6):1426-1430.
50. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000;25(7):717-722.
51. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990; 75(3):555-562.
52. Gitelson E, Hammond C, Mena J, et al. Chronic lymphocytic leukemia- reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res. 2003; 9(5):1656-1665.
53. Mayr C, Bund D, Schlee M, et al. Fibromodulin as a novel tumorassociated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood. 2005;105(4):1566-1573.
54. Mikaelsson E, Danesh-Manesh AH, Luppert A, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood. 2005;105(12):4828-4835.
55. ]Giannopoulos K, Li L, Bojarska-Junak A, et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol. 2006; 29(1):95-103.
56. Mayr C, Bund D, Schlee M, et al. MDM2 is recognized as a tumorassociated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol. 2006; 34(1):44-53.
57. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995 85(9):2315-2320.
58. Siegel S, Wagner A, Kabelitz D, et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood. 2003;102(13):4416-4423.
59. Schmidt SM, Schag K, Müller MR, et al. Induction of adipophilinspecific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 2004;64(3):1164-1170.
60. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001;97(9):2777-2783.
61. Krackhardt AM, Witzens M, Harig S, et al. Identification of tumorassociated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002;100(6):2123-2131.
62. Harig S, Witzens M, Krackhardt AM, et al. Induction of cytotoxic Tcell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood. 2001; 98(10):2999-3005.
63. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin frameworkderived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med. 2000; 6(6):667-672.
64. Buhmann R, Nolte A, Westhaus D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999;93(6):1992-2002.
65. Juffs H, Fowler N, Saal R, et al. B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma. Pathology. 2004;36(1):69-76.
66. Williams JF, Petrus MJ, Wright JA, et al. fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous fasL-expressing T cells. Br J Haematol. 1999;107(1):99-105.
67. Foa R, Giovarelli M, Jemma C, et al. Interleukin 2 (IL 2) and interferon- gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population. Blood. 1985;66(3):614-619.
68. Tötterman TH, Carlsson M, Simonsson B, et al. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood. 1989;74(2):786-792.
69. Rossi E, Matutes E, Morilla R, et al. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia. 1996;10(3):494-497.
70. Cantwell M, Hua T, Pappas J, et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3(9):984-989.
71. Schuler M, Tretter T, Schneller F, et al. Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals. Immunobiology. 1999;200(1):128-139.
72. Görgün G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797-1805.
73. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018-2025.
74. Wierda WG, Kipps TJ. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007;20(3): 557-568.
75. Dilloo D, Brown M, Roskrow M, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997;90(5):1927-1933.
76. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96(9):2917-2924.
77. Takahashi S, Rousseau RF, Yotnda P, et al. autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Human Gene Therapy. 2001;12(6):659-670.
78. Biagi E, Dotti G, Yvon E, et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumorreactive cytotoxic T lymphocytes. Blood. 2005;105(6):2436-2442.
79. Tolba KA, Bowers WJ, Hilchey SP, et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood. 2001;98(2):287-295.
80. Wendtner CM, Kofler DM, Theiss HD, et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood. 2002;100(5):1655-1661.
81. Li LH, Biagi E, Allen C, et al. Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells. Cancer Gene Ther. 2006;13(2):215-224.
82. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393(6684):478-480.
83. Wierda WG, Castro JE, Aguillon R, et al. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010; 24(11):1893-1900.
84. Dicker F, Kater AP, Prada CE, et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006;108(10):3450-3457.
85. Biagi E, Rousseau R, Yvon E, et al. Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia. Clin Cancer Res. 2005;11(19 Pt 1):6916-6923.
86. Fratantoni JC, Li L, Liu LN, et al. A practical approach for achieving clinical immunotherapy of CLL with hCD40L- and hIL-2 expressing autologous tumor cells. Blood (ASH Annual Meeting Abstracts). 2005;106:450.
87. Okur FV, Yvon E, Dotti G, et al. Vaccination Strategies for Patients with B-CLL. Blood (ASH Annual Meeting Abstracts). 2008;112:2106.
88. ClinicalTrials.gov. U.S. National Institute of Health. www.clinicaltrials.gov. Accessed September 15, 2011.
89. Nishimura T, Watanabe K, Yahata T, et al. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother Pharmacol. 1996;38(suppl):S27-S34.
90. Stripecke R, Skelton DC, Pattengale PK, et al. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum Gene Ther. 1999;10(13):2109-2122.
91. Vereecque R, Buffenoir G, Preudhomme C, et al. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Ther. 2000;7(15):1312-1316.
92. Palena C, Foon KA, Panicali D, et al. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood. 2005;106(10):3515-3523.
93. Litzinger MT, Foon KA, Sabzevari H, et al. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. Cancer Immunol Immunother. 2009;58(6):955-965.
94. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21(6):873-886.
95. Müller MR, Tsakou G, Grünebach F, et al. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood. 2004;103(5):1763-1769.
96. Rezvany MR, Jeddi-Tehrani M, Wigzell H, et al. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood. 101(3):1063-1070.
97. Palma M, Adamson L, Hansson L, et al. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol Immunother. 2008;57(11):1705-1710.
98. Kokhaei P, Rezvany MR, Virving L, et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic celltumour hybrids in B-CLL. Leukemia. 2003;17(5):894-899.
99. Hus I, Rolinski J, Tabarkiewicz J, et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia. 2005;19(9):1621-1627.
100. Hus I, Schmitt M, Tabarkiewicz J, et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia. 2008;22(5):1007-1017.
101. Kronenberger K, Nössner E, Frankenberger B, et al. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia. J Immunother. 2008;31(8):723-730.
102. Mocikat R, Selmayr M, Thierfelder S, et al. Trioma-based Vaccination against B-Cell Lymphoma Confers Long-Lasting Tumor Immunity. Cancer Research. 1997;57(12):2346-2349.
103. Wahl U, Nössner E, Kronenberger K, et al. Vaccination against Bcell Chronic Lymphocytic Leukemia with Trioma Cells. Clin Cancer Res. 2003;9(11):4240-4246.
104. Gitelson E, Hammond C, Mena J, et al. Chronic Lymphocytic Leukemia- reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines. Clin Cancer Res. 2003;9(5):1656-1665.
105. Spaner DE, Hammond C, Mena J, et al. A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia. Cancer Immunol Immunother. 2005;54(7):635-646.
106. Hus I, Kawiak J, Tabarkiewicz J, et al. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages. Oncol Rep. 2008;20(2):443-451.
107. Campbell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol. 1987;139(8):2825-2833.
108. Greiner J, Li L, Ringhoffer M, et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/ CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood. 2005;106(3):938-945.
109. Greiner J, Ringhoffer M, Taniguchi M, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemiaassociated antigen in acute and chronic myeloid leukemia. Exp Hematol. 2002;30(9):1029-1035.
110. Greiner J, Ringhoffer M, Taniguchi M, et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer. 2003;106(2):224-231.
111. Crainie M, Belch AR, Mant MJ, Pilarski LM. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood. 1999;93(5):1684-1696.
112. Assmann V, Marshall JF, Fieber C, et al. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci. 1998;111(Pt 12):1685-1694.
113. Giannopoulos K, Dmoszynska A, Kowal M, et al. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia. 2010;24(4):798-805.